1. シグナル伝達
  2. Membrane Transporter/Ion Channel
  3. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

製品番号 製品名 製品効果 純度 構造式
  • HY-B1304
    (-)-Sparteine sulfate pentahydrate Inhibitor
    (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate pentahydrate) is a class 1a antiarrhythmic agent and a sodium channel blocker.
    (-)-Sparteine sulfate pentahydrate
  • HY-102998
    Nav1.7-IN-6 Inhibitor
    Nav1.7-IN-6 (example 346) is a Nav1.7 selective inhibitor, which is extracted from patent WO2015078374A1.
    Nav1.7-IN-6
  • HY-126291
    GNE-616 Inhibitor
    GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM Kd and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively.
    GNE-616
  • HY-148370C
    Sefaxersen sodium scrambled negative control Inhibitor
    Sefaxersen sodium scrambled negative control is the sequence scrambled negative control of Sefaxersen sodium.
    Sefaxersen sodium scrambled negative control
  • HY-110032
    Lamotrigine isethionate Inhibitor
    Lamotrigine (BW430C) isethionate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine isethionate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine isethionate can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine isethionate
  • HY-B0495A
    Lamotrigine hydrate Inhibitor
    Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine hydrate
  • HY-108506S1
    Licarbazepine-d4 Inhibitor
    Licarbazepine-d4 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine-d<sub>4</sub>
  • HY-B0339S
    Primidone-d5 Inhibitor 99.00%
    Primidone-d5 is the deuterium labeled Primidone. Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent.
    Primidone-d<sub>5</sub>
  • HY-B0280S2
    Ranolazine-d3 Inhibitor 99.49%
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
    Ranolazine-d<sub>3</sub>
  • HY-B0246S1
    Carbamazepine-d2 Inhibitor
    Carbamazepine-d2 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent.
    Carbamazepine-d<sub>2</sub>
  • HY-19679A
    Quinacainol dihydrochloride Inhibitor
    Quinacainol dihydrochloride (PK 10139 dihydrochloride) is the dihydrochloride salt form of Quinacainol (HY-19679). Quinacainol dihydrochloride is an inhibitor for sodium current with an EC50 of 95 µM. Quinacainol dihydrochloride exhibits antiarrhythmic activity by affecting the electrophysiological properties of the heart.
    Quinacainol dihydrochloride
  • HY-108502
    KC 12291 hydrochloride Inhibitor
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na+ current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo.
    KC 12291 hydrochloride
  • HY-P5824
    Anthopleurin-C Inhibitor
    Anthopleurin-C (APE 2-1) is a cardiotonic polypeptide that shows a powerful positive inotropic effect.
    Anthopleurin-C
  • HY-P1218
    Phrixotoxin 3 Inhibitor
    Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
    Phrixotoxin 3
  • HY-B0122A
    Topiramate lithium Inhibitor
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate lithium
  • HY-P5177
    GsAF-II Inhibitor
    GsAF-II is a peptide toxin that blocks hERG1 subtype potassium channels in a voltage-dependent manner. GsAF-II blocks Nav1.x subtype sodium channels.
    GsAF-II
  • HY-19463
    F-15845 hydrobromide Inhibitor
    F 15845 hydrobromide is a highly effective persistent sodium current blocker. F 15845 hydrobromide is also a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 hydrobromide can be used for the research of myocardium functional impairment.
    F-15845 hydrobromide
  • HY-170930
    Anticonvulsant agent 9 Inhibitor
    Anticonvulsant agent 9 (compound 4f) is an α1β2γ2 GABAA receptors activator. Anticonvulsant agent 9 activatesα1β2γ2 GABAA receptors with an EC50 of 1.24 μM. Anticonvulsant agent 9 inhibits the inactivation of Nav1.2 channels. Anticonvulsant agent 9 exhibits significant anticonvulsant activities.
    Anticonvulsant agent 9
  • HY-W587755
    Benzylhydrochlorothiazide Inhibitor
    Benzylhydrochlorothiazide is an orally active thiazide diuretic. Benzylhydrochlorothiazide acts on the distal convoluted tubules of the kidneys, inhibiting the reabsorption of sodium chloride, thereby increasing urine output and reducing the body's fluid volume. Benzylhydrochlorothiazide has phototoxicity and a potential risk of skin reactions. Benzylhydrochlorothiazide can cause cell death when exposed to UVA radiation. Benzylhydrochlorothiazide is used in research on hypertension and edema.
    Benzylhydrochlorothiazide
  • HY-P990502
    Anti-SCN11a/Nav1.9 Antibody Inhibitor
    The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-SCN11a/Nav1.9 Antibody
製品番号 製品名 / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.